文献速递胰腺与胆道疾病消化内镜消化道肿瘤与早癌

DNA/RNA二代测序提升肿瘤性胆管狭窄的早期诊断与管理:一项6年前瞻性多中心实时研究

DNA/RNA-Based Next-Generation Sequencing Improves the Early Diagnosis and Management of Neoplastic Bile Duct Strictures: A 6-Year, Prospective, Multi-Institutional, Real-Time Study.
PubMed 文献 · Gastroenterology · 2026-03-27

该6年前瞻性多中心研究采用BiliSeq v2/v3对2116例患者ERCP标本行DNA/RNA二代测序,基于1979例随访发现其对肿瘤性狭窄灵敏度82%、特异度98%,显著优于病理评估(44%/99%),联合病理后灵敏度88%、特异度97%,高危人群灵敏度亦由26%–50%提升至74%–86%。

要点

  • BiliSeq v2/v3对肿瘤性胆管狭窄灵敏度82%、特异度98%,优于病理评估的44%/99%。
  • 联合病理评估后灵敏度升至88%,特异度保持97%。
  • PSC等高危人群灵敏度由病理的26%–50%提升至74%–86%。

核心结论

  • 对ERCP获取标本行BiliSeq v2/v3测序可提高胆管狭窄诊断灵敏度并保持高特异度,尤其在PSC患者中。

研究设计与样本

  • 6年前瞻性多中心实时研究,纳入28家机构2116例患者的2908份ERCP刷检、活检和胆汁标本,采用BiliSeq v2(28个癌症相关基因、167个融合基因)和v3(161个癌症相关基因、763个融合基因),与临床、影像及病理(诊断病理和/或至少1年随访)比较。

主要发现

  • 2865份(99%)标本来自2080例(98%)患者完成BiliSeq v2/v3检测,基于1979例(95%)随访患者,BiliSeq v2/v3诊断肿瘤性狭窄灵敏度82%、特异度98%,病理评估灵敏度44%、特异度99%。
  • BiliSeq v2/v3联合病理评估灵敏度88%、特异度97%。
  • 西班牙裔、胚系携带者和PSC等高危人群,BiliSeq v2/v3灵敏度74%–86%,病理评估26%–50%。
  • 20%的BiliSeq v3阳性肿瘤检出可操作分子改变,其中30%病例因此改变患者管理。

关键数值与推荐

  • BiliSeq v2/v3诊断肿瘤性狭窄:灵敏度82%、特异度98%(基于1979例随访患者)。
  • 病理评估:灵敏度44%、特异度99%。
  • BiliSeq v2/v3联合病理:灵敏度88%、特异度97%。
  • 高危人群(西班牙裔、胚系携带者、PSC):BiliSeq v2/v3灵敏度74%–86%,病理26%–50%。
  • BiliSeq v3阳性肿瘤中20%检出可操作分子改变,30%病例管理因此改变。

临床怎么用

  • 对ERCP获取的刷检、活检或胆汁标本可加做BiliSeq v2/v3测序,与病理联合评估以提高肿瘤性胆管狭窄检出。
  • PSC、胚系携带者及西班牙裔等高危患者可优先考虑分子检测以弥补病理灵敏度不足。
  • BiliSeq v3阳性肿瘤中检出可操作分子改变者可能据此调整治疗管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The distinction between benign and neoplastic bile duct strictures remains challenging. Pathologic assessment of endoscopic retrograde cholangiopancreatography (ERCP)-obtained specimens has limited sensitivity, particularly among patients with primary sclerosing cholangitis (PSC). Next-generation sequencing of bile duct specimens provides a promising diagnostic approach, but a prospective, multi-institutional, and comprehensive DNA/RNA analysis is lacking. METHODS: A 6-year, prospective, multi-institutional study was conducted using BiliSeq version 2 (28 cancer-associated genes and 167 fusion genes) and BiliSeq version 3 (161 cancer-associated genes and 763 fusion genes) for 2908 ERCP-obtained brushings, biopsies, and bile from 2116 patients at 28 medical institutions. Molecular results were compared with clinical, imaging, and pathologic parameters including diagnostic pathology and/or at least 1-year follow-up. RESULTS: BiliSeqV2/V3 testing was performed for 2865 (99%) specimens from 2080 (98%) patients. Based on follow-up from 1979 (95%) patients, BiliSeq version 2/version 3 demonstrated 82% sensitivity and 98% specificity for a neoplastic stricture. In comparison, pathologic assessment had a sensitivity of 44% and a specificity of 99%. Combining BiliSeq version 2/version 3 testing with pathologic assessment improved the sensitivity to 88% and maintained a high specificity of 97%. High-risk populations, such as Hispanic, germline carrier, and PSC patients, also showed improvement in sensitivity with BiliSeq version 2/version 3 (74% to 86%) compared with pathologic assessment (26% to 50%). Further, actionable molecular alterations were identified in 20% of BiliSeq version 3-positive neoplasms and modified patient management in 30% of these cases. CONCLUSIONS: Applying BiliSeq version 2/version V3 testing to ERCP-obtained specimens improved the diagnostic evaluation of bile duct strictures, achieving higher sensitivity, especially for PSC, and maintained high specificity compared with traditional methods. This study highlights the importance of next-generation sequencing for precise diagnosis and therapeutic intervention.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Das R, Kleinberger J, Sawas T, et al. DNA/RNA-Based Next-Generation Sequencing Improves the Early Diagnosis and Management of Neoplastic Bile Duct Strictures: A 6-Year, Prospective, Multi-Institutional, Real-Time Study. Gastroenterology. 2026. PMID: 41905432. doi:10.1053/j.gastro.2026.02.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。